WORCESTER, Mass., Aug. 22, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) announced today that its wholly-owned immunotherapy subsidiary, Antigen Express, Inc., has entered into an agreement with the University of Rochester as part of the Antigen Express efforts to develop a novel vaccine against the potentially pandemic avian influenza. The collaboration brings together Dr. John Treanor, an internationally recognized leader in the clinical development of pandemic influenza vaccines, and the novel peptide vaccine technology pioneered by Antigen Express. Dr. Treanor is Professor of Medicine, and of Microbiology and Immunology, in the Department of Medicine at the University of Rochester Medical Center.
